Business Context and Reporting Period
This Form 8-K reports on the results of the 2019 Annual Meeting of Shareholders held by Rexahn Pharmaceuticals, Inc. on June 6, 2019. The filing details the voting outcomes for director elections and the ratification of the independent registered public accounting firm.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
On the record date, there were 4,019,141 shares of common stock outstanding. Shareholders holding 2,898,926 shares were present in person or by proxy.
Proposal 1: Election of Directors
All seven nominees were elected to serve one-year terms expiring at the 2020 Annual Meeting. Significant broker non-votes (2,365,809) were recorded for all nominees.
| Director | For | Withhold | Broker Non-Votes |
|---|---|---|---|
| Charles Beever | 446,331 | 86,786 | 2,365,809 |
| Peter Brandt | 445,231 | 87,886 | 2,365,809 |
| Kwang Soo Cheong | 445,954 | 87,163 | 2,365,809 |
| Ben Gil Price | 447,705 | 85,412 | 2,365,809 |
| Richard J. Rodgers | 448,150 | 84,967 | 2,365,809 |
| Lara Sullivan | 449,060 | 84,057 | 2,365,809 |
| Douglas J. Swirsky | 447,193 | 85,924 | 2,365,809 |
Proposal 2: Ratification of Auditors
The appointment of Baker Tilly Virchow Krause, LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2019, was ratified.
- For: 2,727,259
- Against: 126,138
- Abstain: 45,529
- Broker Non-Votes: None
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Investor Verification Checklist
- Verify the definitive proxy statement filed on April 29, 2019, for detailed biographies of the elected directors.
- Confirm the high volume of broker non-votes (approx. 2.36 million shares) relative to the total outstanding shares.
- Review the Company's subsequent filings for financial performance data, as this 8-K contains no financial metrics.
- Confirm the engagement terms with Baker Tilly Virchow Krause, LLP for the 2019 fiscal year.